BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 25242775)

  • 21. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
    Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
    World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation.
    Dodson SF; de Vera ME; Bonham CA; Geller DA; Rakela J; Fung JJ
    Liver Transpl; 2000 Jul; 6(4):434-9. PubMed ID: 10915164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database.
    Park GC; Hwang S; Kim MS; Jung DH; Song GW; Lee KW; Kim JM; Lee JG; Ryu JH; Choi DL; Wang HJ; Kim BW; Kim DS; Nah YW; You YK; Kang KJ; Yu HC; Park YH; Lee KJ; Kim YK
    J Korean Med Sci; 2020 Feb; 35(6):e36. PubMed ID: 32056398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.
    Angus PW; McCaughan GW; Gane EJ; Crawford DH; Harley H
    Liver Transpl; 2000 Jul; 6(4):429-33. PubMed ID: 10915163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.
    Stärkel P; Stoffel M; Lerut J; Horsmans Y
    Liver Transpl; 2005 Oct; 11(10):1228-34. PubMed ID: 16184571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation.
    Marzano A; Marengo A; Andreone P; Volpes R; Canova D; Cursaro C; Riili A; Fiorentino B; Bacci M; Guazzini S; Burra P
    Minerva Med; 2010 Dec; 101(6):373-83. PubMed ID: 21196896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-HBs response to hepatitis B immunoglobulin prophylaxis in liver transplant recipients.
    Varghese J; Reddy MS; Cherian T; Vijaya S; Jayanthi V; Rela M
    Indian J Gastroenterol; 2014 May; 33(3):226-30. PubMed ID: 24760685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Very Short Course of HBIg+NA Followed by Entecavir or Tenofovir Monotherapy Prevents HBV Recurrence in Low-Risk Liver Transplant Recipients.
    Manini MA; Bruce M; Whitehouse G; Mazzarelli C; Considine A; Agarwal K; Suddle A; Fagiuoli S; Heaton N; Heneghan M
    Transplant Proc; 2021; 53(1):207-214. PubMed ID: 32605776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration.
    Rosenau J; Kreutz T; Kujawa M; Bahr MJ; Rifai K; Hooman N; Finger A; Michel G; Nashan B; Kuse ER; Klempnauer J; Tillmann HL; Manns MP
    J Hepatol; 2007 Apr; 46(4):635-44. PubMed ID: 17316869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation.
    Hooman N; Rifai K; Hadem J; Vaske B; Philipp G; Priess A; Klempnauer J; Tillmann HL; Manns MP; Rosenau J
    Liver Transpl; 2008 Apr; 14(4):435-42. PubMed ID: 18383078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection: A Prospective, Multicenter Study.
    De Simone P; Romagnoli R; Tandoi F; Carrai P; Ercolani G; Peri E; Zamboni F; Mameli L; Di Benedetto F; Cillo U; De Carlis L; Lauterio A; Lupo L; Tisone G; Prieto M; Loinaz C; Mas A; Suddle A; Mutimer D; Roche B; Wartenberg-Demand A; Niemann G; Böhm H; Samuel D
    Transplantation; 2016 Jul; 100(7):1507-12. PubMed ID: 27023394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
    Cholongitas E; Vasiliadis T; Antoniadis N; Goulis I; Papanikolaou V; Akriviadis E
    Transpl Infect Dis; 2012 Oct; 14(5):479-87. PubMed ID: 22624695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review.
    Cholongitas E; Goulis J; Akriviadis E; Papatheodoridis GV
    Liver Transpl; 2011 Oct; 17(10):1176-90. PubMed ID: 21656655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety.
    Darweesh SK; Gad AA; Akroof K; ElLatif ZA
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):607-612. PubMed ID: 30724767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
    Karasu Z; Ozacar T; Akyildiz M; Demirbas T; Arikan C; Kobat A; Akarca U; Ersoz G; Gunsar F; Batur Y; Kilic M; Tokat Y
    Antivir Ther; 2004 Dec; 9(6):921-7. PubMed ID: 15651751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
    Khemichian S; Hsieh MJ; Zhang SR; Limurti J; Kim J; Fong TL
    Dig Dis Sci; 2015 Sep; 60(9):2807-12. PubMed ID: 25939541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis.
    Rodríguez-Tajes S; García-Eliz M; Marcos AC; Campos-Varela I; Ros AC; Loinaz C; Gómez Bravo MÁ; Rodríguez-Perálvarez M; Fabrega E; González Diéguez ML; Vinaixa C; Pascasio JM; Vázquez IF; Baliellas C; Castells L; Salcedo M; Prieto M; Crespo G; Lens S; Forns X
    Liver Int; 2024 Feb; 44(2):279-285. PubMed ID: 38100141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral treatment for hepatitis B virus recurrence following liver transplantation.
    Lee S; Kwon CH; Moon HH; Kim TS; Roh Y; Song S; Shin M; Kim JM; Park JB; Kim SJ; Joh JW; Lee SK
    Clin Transplant; 2013; 27(5):E597-604. PubMed ID: 24093615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation.
    Yuefeng M; Weili F; Wenxiang T; Ligang X; Guiling L; Hongwei G; Wencai L; Xiaoguang W; Wei M; Zhongyi F
    Clin Transplant; 2011; 25(4):517-22. PubMed ID: 20560989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
    Idilman R; Akyildiz M; Keskin O; Gungor G; Yilmaz TU; Kalkan C; Dayangac M; Cinar K; Balci D; Hazinedaroglu S; Tokat Y
    Clin Transplant; 2016 Oct; 30(10):1216-1221. PubMed ID: 27409074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.